37results about How to "Prolong the mean survival time" patented technology

The invention provides a method of clustering the moving ad hoc network based on the state mechanism, belonging to the wireless communication field in the communication technology. The method respectively grades three factors of the mobility of the node, the size of the cluster and the energy of the node, combines the three factors and puts forward a node state mechanism. According to the node state, two kinds of node identities of Register and Guest are prescribed, and a cluster head, backup cluster heads and cluster members from the nodes of Register identity are selected; while from the nodes of Guest identity, the nearest cluster members are selected as the access points, which join the corresponding cluster through two jumps. The invention is superior to the traditional method in respects of the average survival time of the cluster and the balance degree of the cluster, and improves the performance of the network.

A Chinese medicine as an immune regulator used for preparing the antineoplastic Chinese medicine is prepared from astragalus root and acanthopanax bark through decocting, concentrating, depositing inalcohol, and extracting from its deposit by alcohol. Its advnatage is high effect on improving immunity and playing its synergistic role in chemicotherapy and radiotherapy.

The invention relates to a wireless ad hoc network route searching method and a system thereof. The method comprises the steps that a source node broadcasts RREQ to a neighboring node; if the neighboring node is a target node, the minimum remaining energy and the average remaining energy are updated, and RREP is sent to the source node; otherwise, if the forwarding time is less than a first threshold, the neighboring node is used as a route path node, and the minimum remaining energy and the average remaining energy are updated; the route hop count is added with 1, and the RREQ is forwarded tothe neighboring node; after the source node receives the RREP, a routing table is updated; if the difference of the average remaining energy in each route path is less than a second threshold, a route path with the smallest number of route hops is selected as the optimal route path; otherwise, a route path with the maximum average remaining energy is selected as the optimal route path. By comprehensively considering the distance from the source node to the destination node, the remaining energy of each node and the average remaining energy, the energy consumption of each node is balanced. Network partition is avoided, which improves the average lifetime of nodes.

The invention relates to an analogue virus, in particular to an FAT10 gene siRNA recombination analogue virus as well as a preparation method and application thereof. The analogue virus is a compound of a fusion peptide and an FAT10 gene siRNA recombination expression vector, wherein the fusion peptide is formed by connecting an RGD peptide and a cell-penetrating peptide HIV-Tat49-57; and the FAT10 gene siRNA recombination expression vector controls the expression of the FAT10 gene siRNA through an alpha fetoprotein promoter. The analogue virus can target hepatocarcinoma cells and limit the expression of the FAT10 gene siRNA in the hepatocarcinoma cells and cause silent expression of the FAT10 gene in the hepatocarcinoma cells because of the specificity to avoid the damage to the irrelevant cells, and has the advantages of high transfection efficiency, simple and time-saving preparation method, and the like. The analogue virus can be used for preparing anti-cancer drugs and has good prospect in development and application in the field of the gene therapy of liver cancers.

The invention relates to a construction method of a dyskinesia phenotypic GTP cyclohydrolase (GTPCH) enzyme defective mouse model. The construction method comprises the steps that (1) Gch1 p.Leu108Argheterozygous mutant mice are obtained, leucine codon at 108 position of Gch1 genes of the heterozygous mutant mice is mutated into arginine codon; (2) the heterozygous mutant mice are hybridizedwith wild-type mice of other strains, and F1-generation heterozygous mutant mice are screened; and (3) the F1-generation heterozygous mutant mice are inbred, and F2-generation homozygote mutant mice are screened. According to the construction method, the deadly problem of GTPCH enzyme defective embryos in the development process can be avoided, and the birth rate of the homozygote mutant mice canreach or close to the expected proportion of Mendel; and at the same time, the mice with different genetic background are hybridized, the survival of F2-generation mice after birth can further be improved, and the average survival period is prolonged.

The invention particularly relates to a siRNA for restaining the TOX wx 2 gene expression and an application of the siRNA to the screening of the TOX attenuated virus or toxicity-decreasing living vaccine. A pair of 60 ribonucleotide barrette-shaped DNA respectively containing 9 basic group palindrome structures is designed according to the 895 to 913 position sequence of the TOX wx 2 gene (the accession number of GenBank is AY238892). The barrette-shaped DNA is adopted to produce interfering particles which are guided into the TOX body by the electroporation method to obtain the RNA interfering TOX strain wx 2b-I capable of expressing the siRNA continuously in the TOX body, the animal infection experiment shows that the toxicity of the TOX is reduced evidently; the surviving time of a mouse with the toxicity is evidently longer than the negative control and wild type TOX strain; the attenuated virus or toxicity-decreasing living vaccine used for the cattle and pets are hopeful to be explored.

The invention relates to the technical field of animal model construction, in particular to a construction method and application of a glycogen accumulation disease Ib type gene point mutation mouse model. A homozygous mouse model with SLC37A4 gene point mutation is obtained by a method of hybridizing a heterozygous mouse with the SLC37A4 gene point mutation with other strains of wild type mice, and is used for truly simulating clinical diseases of patients with glycogen accumulation disease Ib caused by SLC37A4 gene defects due to the SLC37A4 gene point mutation. The point mutation mouse model obtained by adopting the construction method can be applied to research on pathogenesis of the glycogen accumulation disease Ib and development of drugs for treating the glycogen accumulation disease Ib.

The invention belongs to the gene engineering field, and discloses a capsid chimeric protein HPV16 L1-PD, the preparation method thereof and the application thereof. HPV16 L1-PD has an amino acid sequence shown as SEQ ID No.2; and the encoding gene thereof has a nucleotide sequence shown as SEQ ID No.1. The preparation method comprises the steps as follows: constituting HPV16 L1-PD gene; cloning the HPV16 L1-PD gene; constituting a recombination carrier pFastBacDual HPV16 L1-PD; preparing the recombined baculovirus containing the HPV16 L1-PD gene; expressing in insect cells; purifying HPV16 L1-PD, etc. HPV16 L1-PD can be adopted as a gene or a pharmaceutical target carrier and a vaccine transfer tool, and can be applied in preparing the therapeutic virus-like vaccine of systemic lupus erythematosus.

The present invention relates to enhancement of anti-tubercular activity of active fraction isolated from Salicornia brachiata. The invention also discloses the non-toxic nature of the fraction and positively identifies Sucrose as its main constituent. Pure Sucrose is shown to have no anti-tubercular activity indicating thereby that activity of the fraction resides in one or more of the minor constituents. The minor constituents are shown to be relatively low molecular weight entities and a chromatographic technique is disclosed for separating them from the bulk sucrose to probe their activities and structures in detail, as also the possibility of their synthesis if the leads thrown up are novel.

The invention relates to a traditional Chinese medicine composition with qi-tonifying and blood-nourishing effects and a preparation method thereof. The traditional Chinese medicine composition is prepared by processing radix codonopsis, radix rehmanniae preparata, radix angelicae sinensis, poria cocos, radix paeoniae alba, rhizoma atractylodis macrocephalae stir-fried with bran, rhizoma chuanxiong and licorice roots. The traditional Chinese medicine composition has the effects of tonifying qi and nourishing the blood and is used for qi-blood deficiency, sallow complexion, inappetence, limb weakness, menometrorrhagia and the like. The traditional Chinese medicine composition does not contain ethyl alcohol and is small in irritation to gastrointestinal tracts and suitable for females not good at drinking, patients who have gastrointestinal ulcers and the like and need to be prohibited from drinking wine and people who have allergy to alcohol for drinking.

The present invention relates to the technical field of medicines, particularly to applications of celastrol. The invention provides applications of celastrol in preparation of influenza virus inhibitors and drugs for prevention and/or treatment of influenza virus diseases. According to the present invention, the experimental results show that the celastrol can significantly reduce the mouse death caused by influenza virus infection and prolong the average survival time of the mice, can significantly inhibit mouse lung infection caused by influenza virus infection and effectively relieve the lung infection symptoms of the mice, can treat influenza, pneumonia and other respiratory tract infection diseases caused by influenza virus, can prevent the proliferation and the spread of viruses in vivo and protect normal tissue from injury, and can prevent the occurrence of viral infectious diseases.

The invention discloses a mesylate protein kinase receptor EphA2 dominant epitope compound and a preparation method and application thereof in preparing a therapeutic vaccine for tumor. The compound is prepared from EphA258-66 epitope fusion peptide, EphA2550-558 epitope fusion peptide and EphA2253-261 epitope fusion peptide in mol ratio of 1:1:1 and an LIGHT gene recombinant eukaryotic expression vector; the EphA258-66/550-558/253-261 epitope fusion peptides are respectively prepared from EphA258-66/550-558/253-261 epitopes and a transmembrane sequence HIV-Tat49-57, an endoplasmic reticulum retention signal sequence KDEL and a linker sequence AAY; the combination of the three EphA2 dominant epitopes can effectively overcome the deficiency of a single epitope on immune effect; the three epitope fusion peptides can enter the kytoplasm under the guide action of the transmembrane sequence, target the endoplasmic reticulum under the action of the endoplasmic reticulum retention signal sequence, and efficiently enter an MHC-I (major histocompatibility complex-class I) antigen presenting route; and the LIGHT gene recombinant eukaryotic expression vector can express LIGHT protein in vivoand play a role of a molecular adjuvant to promote the immune response of epitope specific T cells.

An implant system for photodynamic therapy with a light source for radiating light which is implantable in a resection cavity, and with an autonomous control unit which is connectable via a supply line to the light source.

The invention discloses a cationic polypeptide-heat shock protein-miRNA tumor gene compound as well as a preparation method and application thereof. The compound is formed by combining cationic polypeptide, heat shock protein Grp78 and miR-125a through non-covalent bonds, and the compound can be recognized by antigen presenting cells, induce powerful anti-tumor immunity and effectively inhibit growth of tumor cells; and the compound is simple to prepare, can be used for preparing tumor therapeutic gene compounds, and has good development and application prospects in the field of tumor treatment.